A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

NCT06668324 ·Status: COMPLETED

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

NCT06486779 ·Status: RECRUITING

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

NCT05776888 ·Status: ACTIVE_NOT_RECRUITING

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657 ·Status: COMPLETED

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

NCT05285904 ·Status: COMPLETED

Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis

NCT06644638 ·Status: COMPLETED

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

NCT05171972 ·Status: COMPLETED

Characterizing the Use of Ofatumumab in a Real World Setting

NCT05090033 ·Status: COMPLETED

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

NCT07389590 ·Status: RECRUITING ·Phase: PHASE4

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

NCT07074886 ·Status: RECRUITING ·Phase: PHASE2

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

NCT03157830 ·Status: COMPLETED

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

NCT04788615 ·Status: COMPLETED ·Phase: PHASE3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

NCT06869785 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

NCT02792218 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 ·Status: RECRUITING ·Phase: PHASE3

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

NCT05266469 ·Status: COMPLETED

A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

NCT06854341 ·Status: COMPLETED

WOE of Anti-CD20 Therapies

NCT06121349 ·Status: COMPLETED

A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab

NCT07504783 ·Status: ACTIVE_NOT_RECRUITING

Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis

NCT06159712 ·Status: RECRUITING ·Phase: NA

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

NCT04486716 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231 ·Status: COMPLETED ·Phase: PHASE3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04878211 ·Status: TERMINATED ·Phase: PHASE4